So far, minimal residual disease (MRD) has not been used much outside of clinical trials, but researchers are testing how it might be used to guide decisions in clinical practice, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
So far, minimal residual disease (MRD) has not been used much outside of clinical trials, but researchers are testing how it might be used to guide decisions in clinical practice, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
Transcript
How can MRD being used to tailor therapy for patients with CLL? And is this being used in the real-world or most in clinical trials?
MRD, really at this point, has been a tool used for decision making in the context of clinical trials. More challenging in clinical practice, just given availability of testing and all of these things. So, right now I think the major use is in clinical trials, but I think as we know more about how MRD should inform our decision making it will become more a piece of clinical practice.
You were part of a team of authors on an abstract proposing a trial to assess MRD for the purpose of guiding clinical decision making. What was involved in that trial design and how would it help guide future decisions?
So, this is a really exciting study. We’re looking at patients who’ve [received a] commercial supply of venetoclax, either alone or in combination with a CD20 antibody, and 4 patients who have received this therapy will be testing MRD. And if patients have really achieved a deep level of response, they’ll be able to come off drug, and we’ll monitor MRD serially. We’re going to wait until patients really progress to re-treat the with venetoclax, but we will be seeing what the kinetics of that MRD is after stopping venetoclax.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More